Khemani Robinder G, Randolph Adrienne, Markovitz Barry
Department of Anesthesiology Critical Care Medicine, Childrens Hospital Los Angeles, 4650 Sunset Blvd Mailstop 12, Los Angeles, California 90027, USA.
Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD001000. doi: 10.1002/14651858.CD001000.pub3.
Post-extubation stridor may prolong length of stay in the intensive care unit, particularly if airway obstruction is severe and re-intubation proves necessary. Some clinicians use corticosteroids to prevent or treat post-extubation stridor, but corticosteroids may be associated with adverse effects ranging from hypertension to hyperglycaemia, so a systematic assessment of the efficacy of this therapy is indicated.
To determine whether corticosteroids are effective in preventing or treating post-extubation stridor in critically ill infants, children, or adults.
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL and reference lists of articles. The most recent searches were conducted in January 2009.
Randomized controlled trials comparing administration of corticosteroids by any route with placebo in infants, children, or adults receiving mechanical ventilation via an endotracheal tube in an intensive care unit.
Three review authors independently assessed trial quality and extracted data.
Eleven trials involving 2301 people were included: six in adults, two in neonates, three in children. All but one examined use of steroids for the prevention of post-extubation stridor; the remaining one concerned treatment of existing post-extubation stridor in children. Patients were drawn from heterogeneous medical/surgical populations. Dexamethasone given intravenously at least once prior to extubation was the most common steroid regimen utilized (uniformly in neonates and children). In neonates the two studies found heterogeneous results, with no overall statistically significant reduction in post extubation stridor (RR 0.42; 95% CI 0.07 to 2.32). One of these studies was on high-risk patients treated with multiple doses of steroids around the time of extubation, and this study showed a significant reduction in stridor. In children, the two studies were clinically heterogeneous. One study included children with underlying airway abnormalities and the other excluded this group. Prophylactic corticosteroids tended to reduce reintubation and significantly reduced post-extubation stridor in the study that included children with underlying airway abnormalities (N = 62) but not in the study that excluded these children (N = 153). In six adult studies (total N = 1953), the use of prophylactic corticosteroid administration did not significantly reduce the risk of re-intubation (RR 0.48; 95% CI 0.19 to 1.22). While there was a significant reduction in the incidence of post extubation stridor (RR 0.47; 95% CI 0.22 to 0.99), there was significant heterogeneity (I(2)=81%, X(2)=26.36, df=5, p<0.0001). Subgroup analysis revealed that post extubation stridor could be reduced in adults with a high likelihood of post extubation stridor when corticosteroids were administered as multiple doses begun 12-24 hours prior to extubation compared to single doses closer to extubation; the test for interaction for multiple versus single doses indicated RRR 0.22 (95% CI 0.10 to 0.47) for stridor with multiple doses. Side effects were uncommon and could not be aggregated.
AUTHORS' CONCLUSIONS: Using corticosteroids to prevent (or treat) stridor after extubation has not proven effective for neonates or children. However, given the consistent trends towards benefit, this intervention does merit further study, particularly for high risk children or neonates. In adults, multiple doses of corticosteroids begun 12-24 hours prior to extubation do appear beneficial for patients with a high likelihood of post extubation stridor.
拔管后喘鸣可能会延长重症监护病房的住院时间,尤其是在气道梗阻严重且有必要再次插管的情况下。一些临床医生使用皮质类固醇来预防或治疗拔管后喘鸣,但皮质类固醇可能会带来从高血压到高血糖等一系列不良反应,因此有必要对这种治疗方法的疗效进行系统评估。
确定皮质类固醇在预防或治疗危重症婴儿、儿童或成人拔管后喘鸣方面是否有效。
我们检索了Cochrane对照试验中心注册库、MEDLINE、EMBASE、CINAHL以及文章的参考文献列表。最近一次检索于2009年1月进行。
在重症监护病房接受经气管插管机械通气的婴儿、儿童或成人中,比较通过任何途径给予皮质类固醇与安慰剂的随机对照试验。
三位综述作者独立评估试验质量并提取数据。
纳入了11项涉及2301人的试验:6项针对成人,2项针对新生儿,3项针对儿童。除一项试验外,其余所有试验均研究了使用类固醇预防拔管后喘鸣;其余一项试验关注儿童现有拔管后喘鸣的治疗。患者来自不同的内科/外科人群。拔管前至少静脉注射一次地塞米松是最常用的类固醇给药方案(在新生儿和儿童中均如此)。在新生儿中,两项研究结果不一致,拔管后喘鸣总体上没有统计学显著降低(风险比0.42;95%置信区间0.07至2.32)。其中一项研究针对在拔管前后接受多剂量类固醇治疗的高危患者,该研究显示喘鸣显著减少。在儿童中,两项研究在临床上存在异质性。一项研究纳入了有潜在气道异常的儿童,另一项研究排除了这一群体。预防性皮质类固醇在纳入有潜在气道异常儿童的研究(n = 62)中倾向于减少再次插管并显著降低拔管后喘鸣,但在排除这些儿童的研究(n = 153)中并非如此。在六项成人研究(共n = 1953)中,使用预防性皮质类固醇给药并未显著降低再次插管的风险(风险比0.48;95%置信区间0.19至1.22)。虽然拔管后喘鸣的发生率显著降低(风险比0.47;95%置信区间0.22至0.99),但存在显著异质性(I² = 81%,X² = 26.36,自由度 = 5,p < 0.0001)。亚组分析显示,与更接近拔管时给予单剂量相比,在拔管前12 - 24小时开始给予多剂量皮质类固醇时,拔管后喘鸣可能性高的成人中拔管后喘鸣可减少;多剂量与单剂量的交互作用检验表明,多剂量时喘鸣的相对危险度降低0.22(95%置信区间0.10至0.47)。副作用不常见且无法汇总。
使用皮质类固醇预防(或治疗)拔管后喘鸣对新生儿或儿童尚未证实有效。然而,鉴于一致的获益趋势,这种干预措施确实值得进一步研究,特别是对于高危儿童或新生儿。在成人中,拔管前12 - 24小时开始给予多剂量皮质类固醇对拔管后喘鸣可能性高的患者似乎有益。